Navigation Links
Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
Date:7/17/2012

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately.  Mr. Ripley will lead licensing, partnering initiatives, intellectual property analysis and act as the internal coordinator of the emricasan commercialization strategy development.

"Dan brings experience in both in-licensing and out-licensing of commercial products as well as extensive experience in partnering early-to-late stage products", said Steven J. Mento, Ph.D., President and CEO. "His varied experience in drug development transactions will be particularly important as we move forward with the development of emricasan, our first-in-class caspase inhibitor, into Phase 3 clinical trials for acute liver failure and liver fibrosis, and the related coordination of its commercialization activities".

We also want to continue our strong track record of success with collaborative drug discovery partnerships with large pharmaceutical companies, expanding the development of emricasan for disease targets other than liver disease as well as monitoring our collaboration with Abbott Laboratories in cancer," continued Dr. Mento.  "In addition, we have a leadership position in intellectual property related to programmed cell death (apoptosis) including ongoing relationships with thought leaders in the field of apoptosis and in our targeted disease areas. We possess an extensive patent portfolio comprised of over 130 issued patents including patents covering composition of matter on validated drug targets and new chemical entities (NCEs) addressing those targets, as well as broad fields of use, drug-screening assays, diagnostics and antibodies.  Dan will be involved in seeking business opportunities in each of these areas".

For more than a decade, Mr. Ripley has been involved with emerging growth life science companies in the development and execution of strate
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... July 25, 2014  Solanbridge Group Inc (OTC: SLNX) ... majority interest in Buzznbrewz.com and the Letter of Intent ... a fully executed Purchase Agreement. Charles ... are proud to have Mr. David Pecoraro ... experience in the private sector and developed a tremendous ...
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Results of Largest Randomized, Placebo-controlled Trial,Ever Conducted ... of,Clinical Oncology, CHICAGO, June 04, 2007 /PRNewswire/ ... clinical trial ever,conducted in patients with cutaneous ... than twice as effective as placebo in ...
... in Patients With Follicular Lymphoma Reported,Today at ... /PRNewswire/ -- GlaxoSmithKline plc,announced today long-term efficacy ... a,single one-week course of frontline treatment with ... Tositumomab) in,76 patients with newly diagnosed advanced ...
Cached Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... July 28, 2014 Maternal and Family ... Tucker Award, which will be presented at the agency’s ... October 29th at the Westmoreland Club in Wilkes-Barre. , ... Commissioner and long-time employee of MFHS. She dedicated ... political activist, health advocate, and champion for women, children ...
(Date:7/28/2014)... that following a healthy lifestyle may lower childhood cancer ... online in CANCER , a peer-reviewed journal of ... with cancer and adults who had cancer when they ... may influence their long-term health. , Adults who ... increased risk for the metabolic syndrome, a group of ...
(Date:7/28/2014)... As health insurers design their strategies ... exchanges. “Private Exchange Strategies for Insurers: What’s Working? ... Information Services, will provide answers to the big-dollar questions ... future. , Barbara Gniewek, Jonathan Har-Even and Martin Hill ... the private exchange sector — will provide expert presentations ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... nerve fibers regenerate, researchers say , FRIDAY, Dec. 11 (HealthDay ... enables regeneration of injured nerve fibers (axons) in mice, a ... treatments for people with brain and spinal cord injuries. , ... an inhibitor of a growth pathway called mTOR -- in ...
... H1N1 activity, down from 25 states last week, CDC says ... rates continue to drop, U.S. health officials said Friday, with ... states last week and 48 states at the height of ... influenza viruses identified so far continue to be H1N1 swine ...
... , , ABBOTT PARK, Ill., Dec. 11 ... declared a quarterly common dividend of 40 cents per share. , ... since 1924. The cash dividend is payable Feb. 15, 2010, to ... , Abbott has increased its dividend payout for 37 consecutive years - ...
... , , Linton Whitaker, ... 11 Linton Whitaker, M.D., a craniofacial surgeon at The ... recently awarded the prestigious Paul Tessier Medal during the annual ... England. , The Paul Tessier Medal is the highest honor ...
... , , AUSTIN, Texas, ... Medical Solutions, is pleased to offer free upgrades to their customers ... Dragon Medical 10.1 is faster and more stable, providing up ... and is compliant with Windows7, 64bit and 32bit operating systems. New ...
... Ill., Dec. 11 If you have a foot or ankle ... every five Americans suffer some sort of foot problem. These problems ... as pain in the knee, hip or back. , How ... If they hurt, they may be signaling more serious conditions. They ...
Cached Medicine News:Health News:New Hope for Brain, Spinal Cord Injuries 2Health News:Swine Flu Infection Rates Continue to Fall 2Health News:Swine Flu Infection Rates Continue to Fall 3Health News:Children's Hospital Surgeon Receives Prestigious Paul Tessier Medal 2Health News:Recorders.com Offers Free Dragon Medical 10.1 Upgrades 2Health News:Happy Feet are Healthy Feet: Common Sense Tips on Taking Care of Your Feet to Survive the Holiday Season 2
... PROXIMATE Access 55 Articulating Linear Staplers are ... or a thick-tissue green instrument (non-reloadable). Each ... 55mm staple line., ,Benefits include: , ... in narrow male pelvis. , Articulating head ...
... Staplers deliver two staggered rows of titanium staples ... be reloaded up to three times for a ... wire staples for thick tissue. The TLV model ... ,Benefits include: , Parallel jaw closure ensures that ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
Single Use Reloadable Stapler with Titanium Staples., ,The Auto Suture™ PREMIUM MULTIFIRE TA™ stapler has applications in abdominal, gynecological, pediatric and thoracic surgical proced...
Medicine Products: